Literature DB >> 12131154

Quality assurance in immunohistochemistry: results of an interlaboratory trial involving 172 pathologists.

Thomas Rüdiger1, H Höfler, H-H Kreipe, H Nizze, U Pfeifer, H Stein, F E Dallenbach, H-P Fischer, M Mengel, R von Wasielewski, H K Müller-Hermelink.   

Abstract

The practicability of quality assurance in immunohistochemistry and its integration into the diagnostic process were both tested in this Germany-wide interlaboratory trial. One hundred seventy-two pathologists received one hematoxylin and eosin and five unstained slides from five cases; all cases were selected by a panel because immunohistochemistry was required for their final diagnosis. Participants rendered a morphologic diagnosis and then substantiated it immunohistochemically. Stained slides and evaluation sheets were reviewed by the panel, and the diagnostic process was analyzed in individual steps: morphologic diagnosis, selection of antibodies, staining quality, interpretation of stained slides, conclusions, and final diagnosis. Diagnosis-independent immunohistochemical performance was tested using a multisample tissue block (30 samples) that was stained and evaluated for six common antigens. For individual cases, corresponding to their difficulty, 21-89% of the final diagnoses (altogether 57% from 828 diagnoses) were correct. In a statistical analysis, the tentative diagnosis, the interpretation of stains and conclusions drawn from immunohistochemistry, were independent factors in reaching the diagnosis. Sensitivity to detect estrogen receptors on the multisample tissue block was only 48%. However, 24% of the stains were interpreted as falsely negative. The low staining sensitivity was not correlated to the number of correct diagnoses. The major problem of applying immunohistochemistry in surgical pathology appears to be its integration into the diagnostic process and not the staining quality. Both future quality control projects and training will have to regard these integrative requirements. Multisample tissue blocks provide a promising tool to standardize quantitative immunohistochemical parameters, such as receptor or proliferation scores.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12131154     DOI: 10.1097/00000478-200207000-00005

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  23 in total

1.  What's cooking? detection of important biomarkers in HOPE-fixed, paraffin-embedded tissues eliminates the need for antigen retrieval.

Authors:  Torsten Goldmann; Ekkehard Vollmer; Johannes Gerdes
Journal:  Am J Pathol       Date:  2003-12       Impact factor: 4.307

2.  Estrogen and HER-2 receptor discordance between primary breast cancer and metastasis.

Authors:  Lajos Pusztai; Giuseppe Viale; Catherine M Kelly; Clifford A Hudis
Journal:  Oncologist       Date:  2010-11-01

3.  Pathologists' Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer.

Authors: 
Journal:  Breast Care (Basel)       Date:  2010-06-08       Impact factor: 2.860

4.  [Interlaboratory trials for quality assurance of breast cancer biomarkers in Germany].

Authors:  C A Krusche; R von Wasielewski; J Rüschoff; A Fisseler-Eckhoff; H H Kreipe
Journal:  Pathologe       Date:  2008-07       Impact factor: 1.011

5.  [Receptor detection in breast cancer. A decade of quality assurance trials in German-speaking pathology].

Authors:  H H Kreipe
Journal:  Pathologe       Date:  2011-09       Impact factor: 1.011

6.  Implementation of External Quality Assurance Trials for Immunohistochemically Determined Breast Cancer Biomarkers in Germany.

Authors:  Reinhard von Wasielewski; Claudia A Krusche; Joseph Rüschoff; Anette Fisseler-Eckhoff; Hans Kreipe
Journal:  Breast Care (Basel)       Date:  2008-04-15       Impact factor: 2.860

7.  Guideline on the requirements of external quality assessment programs in molecular pathology.

Authors:  J Han van Krieken; Nicola Normanno; Fiona Blackhall; Elke Boone; Gerardo Botti; Fatima Carneiro; Ilhan Celik; Fortunato Ciardiello; Ian A Cree; Zandra C Deans; Anders Edsjö; Patricia J T A Groenen; Outi Kamarainen; Hans H Kreipe; Marjolijn J L Ligtenberg; Antonio Marchetti; Samuel Murray; Frank J M Opdam; Scott D Patterson; Simon Patton; Carmine Pinto; Etienne Rouleau; Ed Schuuring; Silke Sterck; Miquel Taron; Sabine Tejpar; Wim Timens; Erik Thunnissen; Peter M van de Ven; Albert G Siebers; Elisabeth Dequeker
Journal:  Virchows Arch       Date:  2012-12-19       Impact factor: 4.064

8.  Discordance in hormone receptor status among primary, metastatic, and second primary breast cancers: biological difference or misclassification?

Authors:  Dominique Sighoko; Juxin Liu; Ningqi Hou; Paul Gustafson; Dezheng Huo
Journal:  Oncologist       Date:  2014-05-07

9.  A cytomorphological and immunohistochemical profile of aggressive B-cell lymphoma: high clinical impact of a cumulative immunohistochemical outcome predictor score.

Authors:  Sylvia Höller; Heike Horn; Andreas Lohr; Uwe Mäder; Tiemo Katzenberger; Jörg Kalla; Heinz-Wolfram Bernd; Philip Went; M Michaela Ott; Hans Konrad Müller-Hermelink; Andreas Rosenwald; German Ott
Journal:  J Hematop       Date:  2009-09-02       Impact factor: 0.196

10.  ImmunoRatio: a publicly available web application for quantitative image analysis of estrogen receptor (ER), progesterone receptor (PR), and Ki-67.

Authors:  Vilppu J Tuominen; Sanna Ruotoistenmäki; Arttu Viitanen; Mervi Jumppanen; Jorma Isola
Journal:  Breast Cancer Res       Date:  2010-07-27       Impact factor: 6.466

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.